Nicotinic acetylcholine receptors: Therapeutic targets for novel ligands to treat pain and inflammation

Pharmacol Res. 2023 Apr:190:106715. doi: 10.1016/j.phrs.2023.106715. Epub 2023 Mar 1.

Abstract

Nicotinic acetylcholine receptors (nAChRs) have been historically defined as ligand-gated ion channels and function as such in the central and peripheral nervous systems. Recently, however, non-ionic signaling mechanisms via nAChRs have been demonstrated in immune cells. Furthermore, the signaling pathways where nAChRs are expressed can be activated by endogenous ligands other than the canonical agonists acetylcholine and choline. In this review, we discuss the involvement of a subset of nAChRs containing α7, α9, and/or α10 subunits in the modulation of pain and inflammation via the cholinergic anti-inflammatory pathway. Additionally, we review the most recent advances in the development of novel ligands and their potential as therapeutics.

Keywords: Chemotherapy-induced neuropathic pain; Chronic pain; Inflammatory pain; Neuropathic pain; Nicotinic acetylcholine receptor subunits α7, α9, and α10; α-conotoxin RgIA.

Publication types

  • Review
  • Research Support, N.I.H., Extramural

MeSH terms

  • Acetylcholine / metabolism
  • Humans
  • Inflammation / drug therapy
  • Inflammation / metabolism
  • Ligands
  • Pain / drug therapy
  • Receptors, Nicotinic* / metabolism
  • Signal Transduction

Substances

  • Receptors, Nicotinic
  • Acetylcholine
  • Ligands